Skip to main content

COMPASS Pathways plc

corporate_fare Company Profile

COMPASS Pathways plc

CMPS·NASDAQ·Life Sciences·CIK 0001816590

COMPASS Pathways plc is a biotechnology company focused on developing innovative treatments for mental health conditions. The company is developing COMP360 psilocybin treatment, a proprietary formulation of pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. This investigational treatment aims to provide rapid and durable responses for serious mental health conditions, including treatment-resistant depression (TRD), a subset of major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The initial focus is on TRD, addressing patients not adequately served by current treatments. In 2018, COMPASS Pathways received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for COMP360 for TRD. In November 2021, the company announced positive top-line results from its Phase 2b clinical trial evaluating COMP360 for TRD. These results were published in The New England Journal of Medicine on November 3, 2022. This Phase 2b study, the largest randomized, controlled, double-blind psilocybin treatment clinical trial completed to date, evaluated the efficacy and safety of a single dose of COMP360 (25mg or 10mg) compared to 1mg in TRD patients. The trial met its primary endpoint for the 25mg dose, showing a statistically significant and clinically relevant reduction in depressive symptom severity after three weeks against the 1mg dose. In 2025, the company completed enrollment for both pivotal trials in its Phase 3 program for COMP360 in TRD, each including a long-term follow-up component.

COMPASS Pathways plc (NASDAQ:CMPS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CMPS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for CMPS spans 10-Q, 8-K, 10-K, 424B5.

Recent high-impact activity:

  • Compass Completes FDA NDA Submission for Psilocybin Depression Therapy
  • Compass Pathways Q3 Loss Narrows to $9.8M as Cash Builds to $444M
  • Compass Narrows Q3 Loss to $9.8M, Final NDA Filing Due Within Two Weeks
  • COMP360 Phase 3 Shows ~4-Point MADRS Gain; Rollout Targets 8,500 SPRAVATO Sites
  • COMP360 Shows Durable 52-Week Efficacy in Phase 3 COMP005; Stock Jumps 11%

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$287.86M
Diluted EPS
-$3.08
Op. Cash Flow
-$157.24M
Operating Income
-$179.04M
Cash & Equivalents
$149.61M
Total Debt
$31.63M
Debt / Equity
-0.60×
Shares Outstanding
96.09M sh
Source: 10-K · filed 2026-03-24 · accession 0001816590-26-000020

Short Interest & Short Volume

7.73 days to cover

FINRA reported short interest of 17,201,909 shares in CMPS as of the October 30, 2026 settlement, a 2.6% decrease from the prior period — about 7.7 days to cover at its recent average daily volume. On November 20, 2026, 52.4% of CMPS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,201,909 shares as of October 30, 2026
Change vs prior period▼ 2.6%
Days to cover7.73 at avg daily volume of 2,225,686
Daily short volume (FINRA facilities)52.4% of 2,449,725 shares on November 20, 2026
5-day average short volume44.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$8.2 +1.86% today
52-week range · as of 2026-11-03 $4.88 – $15.87
Market cap
$1.14B
Volume
6.1M (1.7× avg)
3-mo avg 3.5M
Live data · 2026-11-22 00:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CMPS - Latest Insights

CMPS
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.90
Real-time Price: $8.20 info
Change: -$0.700 (-8%) info
Market Cap: $1.141B info
CMPS
Nov 03, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.21
Real-time Price: $8.20 info
Change: -$1.01 (-11%) info
Market Cap: $1.141B info
CMPS
Nov 03, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.50
Real-time Price: $8.20 info
Change: -$1.30 (-14%) info
Market Cap: $1.141B info
CMPS
Sep 23, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.75
Real-time Price: $8.20 info
Change: -$6.55 (-44%) info
Market Cap: $1.141B info
CMPS
Sep 09, 2026, 1:18 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $15.30
Real-time Price: $8.20 info
Change: -$7.10 (-46%) info
Market Cap: $1.141B info
CMPS
Aug 05, 2026, 6:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.84
Real-time Price: $8.20 info
Change: -$3.64 (-31%) info
Market Cap: $1.141B info
CMPS
Aug 05, 2026, 6:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $11.84
Real-time Price: $8.20 info
Change: -$3.64 (-31%) info
Market Cap: $1.141B info
CMPS
Jul 07, 2026, 6:43 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $13.80
Real-time Price: $8.20 info
Change: -$5.60 (-41%) info
Market Cap: $1.141B info
CMPS
Jul 07, 2026, 6:33 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $12.86
Real-time Price: $8.20 info
Change: -$4.66 (-36%) info
Market Cap: $1.141B info
CMPS
May 13, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.90
Real-time Price: $8.20 info
Change: -$1.70 (-17%) info
Market Cap: $1.141B info
CMPS
May 13, 2026, 6:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.90
Real-time Price: $8.20 info
Change: -$1.70 (-17%) info
Market Cap: $1.141B info
CMPS
May 13, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $9.90
Real-time Price: $8.20 info
Change: -$1.70 (-17%) info
Market Cap: $1.141B info
CMPS
Apr 18, 2026, 4:33 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $6.93
Real-time Price: $8.20 info
Change: +$1.27 (+18%) info
Market Cap: $1.141B info
CMPS
Mar 24, 2026, 7:30 AM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $5.40
Real-time Price: $8.20 info
Change: +$2.80 (+52%) info
Market Cap: $1.141B info
CMPS
Mar 24, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.40
Real-time Price: $8.20 info
Change: +$2.80 (+52%) info
Market Cap: $1.141B info
CMPS
Feb 19, 2026, 8:50 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.51
Real-time Price: $8.20 info
Change: -$0.310 (-4%) info
Market Cap: $1.141B info
CMPS
Feb 19, 2026, 8:49 AM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $8.62
Real-time Price: $8.20 info
Change: -$0.420 (-5%) info
Market Cap: $1.141B info
CMPS
Feb 17, 2026, 4:46 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $7.13
Real-time Price: $8.20 info
Change: +$1.07 (+15%) info
Market Cap: $1.141B info
CMPS
Feb 17, 2026, 4:08 PM EST
Filing Type: 424B5
Importance Score:
9
Price at Filing: $7.20
Real-time Price: $8.20 info
Change: +$1.000 (+14%) info
Market Cap: $1.141B info
CMPS
Feb 17, 2026, 6:33 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.40
Real-time Price: $8.20 info
Change: +$2.80 (+52%) info
Market Cap: $1.141B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets